Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis
Conditions
Interventions
incabotulinumtoxinA
Placebo
Locations
1
United States
Multiple Sclerosis Center of Northeastern New York
Latham, New York, United States
Start Date
November 1, 2013
Primary Completion Date
January 27, 2016
Completion Date
December 31, 2016
Last Updated
March 22, 2017
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
Multiple Sclerosis Center of Northeastern New York
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions